Shots: The sNDA filing is based on P-III ADVANCE trial data, assessing Otezla (30 mg, bid) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis The P-III ADVANCE study results: @16wks., improvement in its 1EPs of sPGA score; achieve 2EPs i.e, 75% improvement in BSA, change in PASI score Otezla is […]Read More
Shots: The P-II study will evaluate STI-5656 in ~400 patients hospitalized due to COVID-19 having mild, moderate, and severe symptoms. The P-II clinical trials of abivertinib now cleared to proceed in both Brazil and the US The dose to be tested is the same as in the US P-II trial but the trial protocol in […]Read More
Shots: Lupin has launched favipiravir in India under the brand name ‘Covihalt’ for the treatment of mild to moderate COVID-19 Covihalt will be available as 200mg tablets in the form of a strip of 10 tablets, priced at $0.65 (₹49/tablet) and has received DCGI authorization for emergency use Additionally, SunPharma has launched antiviral drug favipiravir […]Read More
Shots: The P-III study assessing the efficacy and safety of Favipiravir + SSC vs SCC in 150 mild to moderate patients, randomized within a 48hour window of testing RT-PCR positive for COVID-19 Results: P-III study the improvement in 1EPs with 28.6% faster viral clearance in the overall population as measured by the median time until […]Read More
Shots: Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR 103/tablet with recommended dose being 1800mg (bid) on day 1, followed by 800mg (bid) up to day 14 Favipiravir demonstrated clinical improvements of up to […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
